Found 81 clinical trials
Adjuvant Avelumab in Merkel Cell Cancer (ADAM)
This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation
- 4 views
- 17 Jun, 2022
- 10 locations
mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)
carcinoma of the stomach, esophagogastric junction (EGJ), or lower third of the esophagus. Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified
- 8 views
- 01 Mar, 2022
- 1 location
Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)
immune system, therefore making the virus susceptible to attack by the immune system. In this study Valproic acid is being combined with an immune therapy, Avelumab. Avelumab is an antibody that targets
- 16 views
- 28 Feb, 2022
- 1 location
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
bladder. The drug in this study is: Avelumab (also known as BAVENCIO®)
- 0 views
- 03 May, 2022
- 2 locations
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
- 2 views
- 23 Mar, 2022
- 7 locations
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
a monocenter, open label, single arm, phase II study of the combination of axitinib with avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic RCC
- 11 views
- 03 Mar, 2022
- 1 location
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab. The study will also be investigating how
- 1 views
- 30 May, 2021
- 1 location
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)
ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
- 3 views
- 30 Apr, 2022
- 4 locations
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been
- 44 views
- 04 Mar, 2022
- 6 locations
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body. Pemetrexed may stop the
- 7 views
- 03 Feb, 2022
- 1 location